IGM Biosciences Investor Relations Material

IGM Biosciences Inc. is a clinical-stage biotechnology company focused on developing a new class of antibody medicines. Using the inherent advantages of the Immunoglobulin M (IgM) antibody structure, IGM Biosciences aims to create "super antibodies" for the treatment of cancer, as well as autoimmune and inflammatory diseases. By reimagining antibody medicines, the company believes it holds the world's most advanced research and development program for engineered therapeutic IgM antibodies. This approach seeks to expand upon and enhance the natural qualities of IgM antibodies, enabling the development of therapeutic antibodies designed to address a range of diseases more effectively. The company's pipeline includes multiple product candidates in various stages of clinical trials, targeting a variety of cancers and diseases through collaborations and license agreements to advance their research and potential treatments. IGM Biosciences is headquartered in Mountain View, California, and its shares are listed on the NASDAQ.